On May 9, 2023, the U.S. FDA granted orphan drug designation to RAD 301 (Ga68-Trivehexin) for imaging in patients with pancreatic ductal adenocarcinoma (PDAC). RAD 301's orphan drug designation builds upon an FDA-approved Phase I clinical trial for pancreatic cancer, scheduled to begin in the U.S. in the coming weeks. Trivehexin is a proprietary peptide molecule that targets αvβ6-integrin, a cellular marker used to investigate tumor invasion and metastatic growth.
RAD 301 is a specific molecular drug that inhibits tumor invasion and metastasis by targeting αvβ6 integrin. αvβ6 integrin is a specific marker present on the surface of tumor cells and is associated with decreased survival in various cancers, and is highly expressed in most pancreatic cancer cells.
